Key result
TAVR added to optimal medical therapy did not reduce the primary endpoint compared to medical therapy alone.
Why the study?
Paradoxical low-flow, low-gradient AS carries an adverse prognosis, but TAVR had never been compared with optimal medical therapy alone in a dedicated randomized trial.
Does TAVR added to OMT reduce all-cause mortality in symptomatic patients with paradoxical low-flow, low-gradient aortic stenosis?
RCT (n=120)
Open-label
Yes
Does TAVR added to OMT reduce all-cause mortality in symptomatic patients with paradoxical low-flow, low-gradient aortic stenosis?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“REBOOT-PARADOX provides the first randomized evidence in a difficult and understudied population, identifies a meaningful signal for reduced morbidity with earlier TAVR, and simultaneously demonstrates why correcting the valve alone may not normalize the prognosis. It moves the field forward while leaving the survival question and optimal timing of intervention unresolved.”
“While early closure left the effect of TAVR on mortality unresolved, the randomized treatment allocation, extended patient-level follow-up, and frequent crossover provide an unusual opportunity to characterize the clinical course following immediate TAVR vs. an initially conservative strategy.”
In an underpowered randomized trial of patients with paradoxical low-flow, low-gradient aortic stenosis, TAVR did not significantly reduce mortality compared to medical therapy but was associated with improved symptoms.
BACKGROUND: Paradoxical low-flow, low-gradient (pLFLG) aortic stenosis (AS) has an adverse prognosis in comparison to other AS subtypes. Transcatheter aortic valve replacement (TAVR) has never been compared with optimal medical therapy (OMT) alone in a dedicated randomized trial in this population. OBJECTIVES: The trial sought to determine whether TAVR added to OMT reduces all-cause mortality in symptomatic patients with pLFLG AS. RESULTS: Of 783 planned patients, 120 (median age 82 years; 53.3% women) were randomized (80 TAVR, 40 OMT). A total of 19 OMT patients eventually crossed over to TAVR, most for symptom progression. The primary endpoint occurred in 29.0% vs 37.1% (HR: 0.83; 95% CI: 0.41-1.66; P = 0.60), and 5-year mortality was 44.9% vs 56.6% (HR: 0.76; 95% CI: 0.43-1.35; P = 0.35). TAVR was associated with improved symptoms (NYHA functional class I/II at 1 year, 83.0% vs 59.0%) and lower cumulative incidence of first endpoint-related rehospitalizations, and there were no differences in functional capacity or quality of life. CONCLUSIONS: Although the effect of TAVR on mortality remains unresolved, these findings support an individualized strategy with close surveillance and timely TAVR upon clinical deterioration in selected patients with pLFLG AS. Adequately powered randomized trials are needed to define the effect of early TAVR on prognosis. (accuRate Evaluation of Benefit with Optimal medical treatment with or withOut Transcatheter valve repair of PARADOXical low flow low gradient aortic stenosis [REBOOT-PARADOX Trial]; NCT03863132).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Mehilli et al. (2026) conducted an RCT in Paradoxical low-flow, low-gradient (pLFLG) aortic stenosis (n=120). Transcatheter aortic valve replacement (TAVR) vs. Optimal medical therapy (OMT) alone was evaluated on All-cause mortality (HR 0.83, 95% CI 0.41-1.66, p=0.60). TAVR added to optimal medical therapy did not reduce the primary endpoint compared to medical therapy alone.
Synapse has enriched 10 related papers. Consider them for comparative context: